دورية أكاديمية
Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis.
| العنوان: | Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis. |
|---|---|
| المؤلفون: | Mead OG; R&D Department, TissueTech Inc., Miami, FL, USA., Tighe S; R&D Department, TissueTech Inc., Miami, FL, USA.; Department of Ophthalmology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.; Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA., Tseng SCG; R&D Department, TissueTech Inc., Miami, FL, USA.; Ocular Surface Center, Miami, FL, USA. |
| المصدر: | Taiwan journal of ophthalmology [Taiwan J Ophthalmol] 2020 Mar 04; Vol. 10 (1), pp. 13-21. Date of Electronic Publication: 2020 Mar 04 (Print Publication: 2020). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medknow Publications Country of Publication: India NLM ID: 101582127 Publication Model: eCollection Cited Medium: Internet ISSN: 2211-5072 (Electronic) Linking ISSN: 22115056 NLM ISO Abbreviation: Taiwan J Ophthalmol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Mumbai : Medknow Publications Original Publication: Taipei : Elsevier |
| مستخلص: | Neurotrophic keratitis (NK), a degenerative disease caused by damage to the trigeminal nerve, abolishes both tearing and blinking reflexes, thus causing the most severe forms of dry eye disease (DED). Conversely, the increasing severity of DED also leads to progressive loss of corneal nerve density, potentially resulting in NK. Both diseases manifest the same spectrum of corneal pathologies including inflammation and corneal epithelial keratitis, which can progress into vision-threatening epithelial defect and stromal ulceration. This review summarizes the current literature regarding outcomes following sutured and sutureless cryopreserved amniotic membrane (AM) in treating DED as well as epithelial defects and corneal ulcers due to underlying NK. These studies collectively support the safety and effectiveness of cryopreserved AM in restoring corneal epithelial health, improving visual acuity in eyes with NK and DED, and alleviating symptomatic DED. Future randomized controlled trials are warranted to validate the above findings and determine whether such clinical efficacy lies in promoting corneal nerve regeneration. Competing Interests: OM, ST, and ST are employees of TissueTech. Dr Tseng has obtained a patent for the method of preparation and clinical uses of amniotic membrane and has licensed the rights to TissueTech, Inc, which procures and processes, and to Bio-Tissue, Inc, which is a subsidiary of TissueTech, Inc, to distribute cryopreserved amniotic membrane for clinical and research uses. (Copyright: © 2020 Taiwan J Ophthalmol.) |
| References: | Cornea. 2005 Aug;24(6):654-60. (PMID: 16015082) Invest Ophthalmol Vis Sci. 2013 Aug 01;54(8):5144-50. (PMID: 23833066) Eye Contact Lens. 2013 Sep;39(5):341-7. (PMID: 23945524) Ophthalmology. 1999 Aug;106(8):1504-10; discussion 1511. (PMID: 10442895) J Cell Physiol. 1999 Jun;179(3):325-35. (PMID: 10228951) Eye (Lond). 2009 Apr;23(4):840-8. (PMID: 18535612) Am J Ophthalmol. 1997 Mar;123(3):303-12. (PMID: 9063239) Coll Antropol. 2002 Jun;26(1):47-54. (PMID: 12137322) Curr Eye Res. 2000 Mar;20(3):173-7. (PMID: 10694891) Korean J Ophthalmol. 1995 Jun;9(1):32-46. (PMID: 7674551) Regul Pept. 2013 Sep 10;186:92-103. (PMID: 23958840) J Biol Chem. 2009 Jul 24;284(30):20136-46. (PMID: 19491101) Exp Eye Res. 2008 Jun;86(6):879-85. (PMID: 18436208) Exp Eye Res. 2013 Oct;115:31-40. (PMID: 23792171) Immunology. 2016 Nov;149(3):320-328. (PMID: 27421990) Semin Ophthalmol. 2014 May;29(3):119-26. (PMID: 23758337) Cornea. 2020 Apr;39(4):479-483. (PMID: 31634228) Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2906-14. (PMID: 10967044) Clin Ophthalmol. 2018 Apr 09;12:677-681. (PMID: 29670328) Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFh1-8. (PMID: 27116665) Ocul Surf. 2016 Jan;14(1):56-63. (PMID: 26387870) J Biol Chem. 2014 May 9;289(19):13531-42. (PMID: 24652286) Cornea. 2002 Jan;21(1):22-7. (PMID: 11805502) Eye (Lond). 2003 Mar;17(2):139-48. (PMID: 12640399) Invest Ophthalmol Vis Sci. 2001 Mar;42(3):634-41. (PMID: 11222521) Br J Ophthalmol. 2001 Mar;85(3):345-9. (PMID: 11222344) Ocul Surf. 2007 Apr;5(2):75-92. (PMID: 17508116) Cornea. 2001 Mar;20(2):197-204. (PMID: 11248830) Br J Ophthalmol. 1998 Jun;82(6):666-75. (PMID: 9797670) Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4695-4702. (PMID: 28910445) Curr Opin Hematol. 2013 Jan;20(1):10-5. (PMID: 23196895) J Ocul Pharmacol Ther. 1996 Winter;12(4):417-23. (PMID: 8951678) J Anat. 1951 Jan;85(1):68-99. (PMID: 14814019) J Biol Chem. 2013 Sep 6;288(36):25792-803. (PMID: 23878196) Graefes Arch Clin Exp Ophthalmol. 2017 Sep;255(9):1771-1778. (PMID: 28528377) Cornea. 2017 Nov;36(11):1383-1386. (PMID: 28834819) Cornea. 1998 Jul;17(4):389-95. (PMID: 9676911) Invest Ophthalmol Vis Sci. 2002 Apr;43(4):987-94. (PMID: 11923238) Br J Ophthalmol. 2000 Aug;84(8):826-33. (PMID: 10906085) Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1758-62. (PMID: 15161837) Clin Exp Ophthalmol. 2017 Jul;45(5):455-463. (PMID: 27957797) Surv Ophthalmol. 2014 May-Jun;59(3):263-85. (PMID: 24461367) Graefes Arch Clin Exp Ophthalmol. 2017 Dec;255(12):2389-2397. (PMID: 28875340) Am J Ophthalmol. 2011 May;151(5):809-822.e1. (PMID: 21310388) Invest Ophthalmol Vis Sci. 2011 Apr 01;52(5):2669-78. (PMID: 21228375) Invest Ophthalmol Vis Sci. 2014 Mar 19;55(3):1647-56. (PMID: 24519420) Cornea. 2005 May;24(4):369-77. (PMID: 15829790) Ocul Surf. 2018 Jan;16(1):132-138. (PMID: 29032001) J Neurosci Res. 2000 Nov 15;62(4):585-90. (PMID: 11070502) J Biol Chem. 2013 Aug 23;288(34):24363-71. (PMID: 23843455) Ophthalmology. 2002 Mar;109(3):508-12. (PMID: 11874752) Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4686-91. (PMID: 27607414) Expert Rev Ophthalmol. 2010 Oct;5(5):645-661. (PMID: 21436959) Br J Ophthalmol. 2001 Dec;85(12):1455-63. (PMID: 11734521) Digit J Ophthalmol. 2019 Jun 8;25(2):21-25. (PMID: 31327933) Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1771-4. (PMID: 15161839) Invest Ophthalmol Vis Sci. 2001 Aug;42(9):1969-74. (PMID: 11481259) Science. 1987 May 29;236(4805):1106-9. (PMID: 3576223) Lab Invest. 2019 Feb;99(2):210-230. (PMID: 30413814) Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):615-623. (PMID: 30735229) Cornea. 1995 Sep;14(5):473-84. (PMID: 8536460) Ocul Surf. 2017 Jul;15(3):276-283. (PMID: 28736335) ScientificWorldJournal. 2010 Sep 01;10:1731-48. (PMID: 20842319) Diabetes. 2014 Dec;63(12):4262-74. (PMID: 25008176) Brain Res. 1987 May;430(1):1-10. (PMID: 3109691) Int Ophthalmol. 2018 Oct;38(5):2219-2222. (PMID: 29101724) Ocul Surf. 2004 Jul;2(3):177-87. (PMID: 17216089) Int J Mol Med. 2019 Apr;43(4):1888-1899. (PMID: 30816491) Invest Ophthalmol Vis Sci. 2012 Jul 24;53(8):4926-31. (PMID: 22695962) Cornea. 2011 Oct;30 Suppl 1:S8-S14. (PMID: 21912234) J Ophthalmol. 2017;2017:6404918. (PMID: 28894606) Cornea. 2008 Apr;27(3):327-33. (PMID: 18362662) Cornea. 2006 Dec;25(10 Suppl 1):S36-40. (PMID: 17001191) J Cataract Refract Surg. 2001 Feb;27(2):310-9. (PMID: 11226800) Br J Ophthalmol. 2003 Oct;87(10):1215-9. (PMID: 14507749) |
| فهرسة مساهمة: | Keywords: Amniotic membrane; corneal ulcer; dry eye; epithelial defect; neurotrophic keratitis |
| تواريخ الأحداث: | Date Created: 20200421 Latest Revision: 20200928 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7158925 |
| DOI: | 10.4103/tjo.tjo_5_20 |
| PMID: | 32309119 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2211-5072 |
|---|---|
| DOI: | 10.4103/tjo.tjo_5_20 |